One of the most exciting new techniques introduced in the last ten years is positron emission tomography (PET). PET provides quantitative, three-dimensional images for the study of specific biochemical and physiological processes in the human body. This approach is analogous to quantitative in vivo autoradiography but has the added advantage of permitting non-invasive in vivo studies. PET scanning requires a small cyclotron to produce short-lived positron emitting isotopes such as oxygen-15, carbon-11, nitrogen-13 and fluorine-18.
Introduction
Positrons (positive electrons) have the physical property of annihilating with negative electrons to produce a back-to-back emission of two gamma rays. These gamma rays travel with an energy of 511 keV in opposite directions along the same axis. Twin gamma ray detectors, coupled electronically, provide a signal only when simultaneously triggered by * Reproduced with kind permission of Pergamon Press from the special issue of Radiation Physics and Chemistry on Radiation and Medicine (1984) . Guest Editors: B. C. Lentle and H. Singh.
two gamma rays on the same axis. These features endow positron emission tomography with unique advantages for locating the source of emission of radioactive tracers in tissues and organs of the body. A further advantage of the technique is that the short physical half-life characteristic of so many positron emitting elements ensures low radiation dosage during their medical use. A further important scientific benefit of positron emission nuclides is the availability of the "metabolic" elements 150, 13N, and 11C
which facilitate a wide range of studies into biochemical processes in living tissues and organs. The incorporation of these or of the halide 18F by radiochemical syntheses into many natural substances such as carbohydrates, amino-acids, or lipids as well as into a large number of drugs gives positron emission techniques a remarkable potential for biochemical investigation in man. It has aptly been termed "living autoradiography".
For positron emission tomography (PET), five interdependent elements are necessary.
Medical cyclotron
The production of positron emitting isotopes with a short half-life, some of them (e.g. Nitrogen-13, Oxygen-15 and their derivatives) in gaseous form, requires a cyclotron unit which for clinical studies should he in a hospital. The production of compact, highly automated, conveniently controlled cyclotrons requiring little maintenance has increased the acceptance of PET in medical research units.
Radioehemistry
Critical to the operation of a PET system is an efficient radiochemical laboratory. Nitrogen-13, Carbon-11, and Oxygen-15 or their derivatives, produced by the cyclotron, are used as radiolabelled tracers to map the distribution of natural substances in the body or the kinetics of drugs. The success of a PET unit relies heavily on the ingenuity of the radiochemical team.
Camera
An imaging device (the "camera") collects the counts that represent the amount of annihilation gamma ray emissions from the head or other parts of the body being scanned by the PET system. The design of these cameras varies greatly. The current trend is towards the use of a circular array of multiple detectors to obtain a slice of the body. Several rings of detectors can be used simultaneously to obtain multiple slices. The complexity of these rings depends upon the level of data handling and, of course, upon the cost of the detector material and associated electronic circuitry. Recent advances in design promise improved resolution which would be vital when mapping concentrations of brain substances such as neurotransmitters or other chemicals specific to certain brain regions.
Computer system
To handle the vast amount of data derived from the camera, a substantial computer capacity is required. More detector rings, more individual crystals per ring, and greater sophistication of imaging reconstruction and analysis will obviously require even greater computer strength.
Clinical cases
The various diseases or physiological circumstances that have been studied by PET research units fall into the following categories: epilepsy, cerebrovascular problems, psychiatric syndromes, brain tumours, dementia, and certain aspects of the dopaminergic system. A much larger list of clinical problems is now being tackled; over the next few years PET will no doubt provide us with a broader understanding of many neurological diseases.
An exciting area of study will involve correlation of PET's images of subtle metabolic changes with the images of brain disorders provided by nuclear magnetic resonance. The combination of these two methods, assisted by computer tomography, promises substantial improvements in the detection and management of many elusive brain disorders.
Pet imaging systems
The idea of imaging tumours through annihilation gamma rays from the positron decay of certain radioisotopes dates from 1951 [1] . The positron interacts with an electron close to the nucleus, the annihilation produces two gamma rays which travel in opposite directions, and these are detected by coincidence counting. In an array surrounding the region to be imaged either a large number of detectors or positron sensitive detectors can be used. Brownell and Sweet in Boston used two planar arrays of detectors on opposite sides of the patient [2] , and employed focal plane tomography to form images. The same techniques were later applied to paired gamma cameras [3] and paired multi-wire proportional counters [4] with lead converters to capture the 511 keV gamma rays.
In 1962 when it became evident that there were insufficient views of the imaged volume to reconstruct an image of the isotope concentration [5, 6] the early Brookhaven device was rearranged into the first ring of detectors. After the development of x-ray CT scanners, linear arrays of detectors arranged in a hexagon [7] became popular. The sides of the hexagon could be moved to improve the linear sampling and rotated to give sufficient views to reconstruct an image using the filtered back-projection technique.
The sampling problems of the ring device were partially solved by half-detector rotation [8] and later completely eliminated by "wobbling" [9, 10] ; i.e. precessing the whole detector array about a circle whose diameter is of the order of the detector spacing.
All PET imaging systems used sodium iodide scintillation crystals until 1977, when bismuth germanate (BGO) [11] was recognized as a much denser if somewhat slower scintillator. It has a stopping power much greater than sodium iodide and, not being hygroscopic, its crystals can be packed closer since hermetic encapsulation is not required. At the Montreal Neurological Institute we built the first BGO PET imaging device [12] initially with one ring of 64 detectors. A second ring was added in 1979. BGO detectors subsequently became the detectors of choice, and the material has been improved recently so that the transparency and light output is now comparable to sodium iodide.
The main drawback of BGO is its relatively slow scintillation decay time of 300 nsec compared with 250 for Nal. This restricts the coincidence resolving time to some extent but, more seriously, increases the detector "dead time" at high count rates. Some studies (e.g. measuring blood flow by the intravenous injection of oxygen-15 labelled water) require high count rates during the 30-40 seconds used to collect the data.
An improvement caesium fluoride only 2.5 nsec. Its hygroscopic and resulted in 1980 [13] with the use of (CsF), which has a decay time of main disadvantage is that it is very detectors must be hermetically sealed to protect them from the moisture in the air. Caesium fluoride is also less dense than BGO. It is, however, so fast that it is possible to measure the difference in arrival time of the two photons so that the position of the annihilation event along the line joining the detectors can be measured with reasonable precision. Although this has been feasible with plastic scintillators, their low density and lack of energy resolution made them useless for PET systems [14] .
The introduction of CsF detectors initiated a new generation of PET devices that collect the "time-offlight" information as well as information from the detector pair involved in each coincidence, and then reconstruct the final image [15] . These devices are used mainly for cardiac studies, since the increase in attenuation over brain studies means that fewer pairs of gamma rays emerge unscattered. This degrades the image quality for a given radiation dose. The "time-of-flight" information improves the accuracy of the final image in two ways: a) it provides an estimate of "both coordinates" in the image plane where each event occurred, whereas conventional devices only indicated that the event occurred "somewhere" on the line joining the two detectors; b) it reduces the effective random counts in each region of the image to those events that could have occurred in that region based on the detector pair timing resolution.
The prospects for "time-of-flight" systems were further enhanced with the discovery of fast scintillation from barium fluoride (BaF:) in the ultraviolet band [15] . Although this radiation requires fast photomultipliers with quartz windows the crystals are non-hygroscopic.
Recent trends in PET design are advancing along two fronts. The common goal is to provide accurate quantitative images with improved spatial resolution. Alternatives are to use small efficient BGO crystals so that the "partial volume effects" of previous devices will be reduced, or BaF2 crystals whose "time-of-flight" information produces a more accurate image with fewer detected events.
The two approaches are well summarized in the Proceedings of the 1982 Workshop on "Time-of-Flight" Tomography [16] and the Symposium on the Application of Bismuth Germanate [17] . The ideal crystal should be nonhygroscopic, with the density of BGO and the speed of BaF2, and should have the property of scintillation in visible light.
This leads to the question of the practical limits of PET imaging.
Spatial resolution
a) The intrinsic resolution is limited to the positron range -the distance between the emitting nucleus and the annihilation event. This depends on the positron energy, but its blurring as defined by the full width at half maximum (FWHM) is less than 0.5 mm for 18-fluorine [18] .
b) Since the positron and electron are travelling at high speed with respect to the detectors, although two gamma rays are emitted at 180 ° with respect to the original particles centre of mass, the angle will be different (-0.5 °) with respect to the stationary detectors. The image blurring effect will be more pronounced in "body scanning devices" which have greater detector separation (about 2 mm FWHM for a 100 cm diameter array).
c) At present the detector size is the major limitation. It has been limited in the past by cost per crystal and photomultiplier tube (PMT) unit, and by the size of the PMT. If these constraints are removed, BGO crystals can be made narrower than BaF2 crystals. Because the probability of a "Compton" interaction is higher within a BaF2 than a BGO crystal the scattered gamma ray is more likely to be scattered into an adjacent crystal. This gives rise to a greater position uncertainty in the case of crystals fabricated with materials with lower atomic numbers. The effective penetration depth of the crystals also degrades the resolution, since most of the incident annihilation radiation is not along the crystal axis. The magnitude of this effect depends upon the ratio of the object size to the detector separation. For this reason increasing the crystal length will not increase the detector efficiency without degrading resolution, especially at the edges. For "time-of-flight" systems, increasing detector length will also blur the timing resolution because the light photons travel more slowly than gamma ray photons in BaF2 crystals (refractive index 1.55) and one cannot be sure where in the crystal the interaction occurs. The size of the PMT limits the crystal size unless several crystals are packed on the same PMT and some auxiliary means is used to determine which crystal recorded the event [19] . The more stringent light collection requirements in "time-of-flight" systems currently require larger PMT's [19] . PMT's with two independent units in the same glass envelope have recently become available [20] .
Replacement of the PMT with a photodiode would considerably reduce both detector size and cost. Such is the case in CT scanners, where only the total integrated light output is required. How-ever with PET the time and amplitude of each pulse must be accurately recorded.
d) The effects of crosstalk between detectors due to Compton scatter and gamma ray penetration can be reduced by introducing heavy metal between the detectors. At the expense of efficiency [21] this improves resolution, especially at the edges of the field of view. In summary it is unlikely that spatial resolution can be reduced below 4 mm over a 25 cm field of view using BGO detectors, or below 7 mm using BaF2 detectors.
Imaging quality and sources of noise
The data from a PET imaging system contain a mixture of true counts from paired unscattered gamma rays, coincident events in which one or both rays are scattered, and random events in which the two gamma rays are collected simultaneously but do not originate from the same annihilation. The final image quality depends on the way the scattered and random events are treated, the number of true counts, the reconstruction filter, and the compensation for attenuation.
A series of recent articles from the UCLA group analyses in detail the sources of noise in PET images [22] [23] [24] [25] .
a) The noise due to scattered gamma rays is reduced by using narrow slices and long collimators, thereby moving the detectors back from the patient [26] . This is done at the expense of efficiency "in plane" and the loss of "cross slices" obtained from coincident events between detectors in adjacent rings. The effect of the scattered radiation on image contrast can be reduced by deconvolving the scatter during reconstruction [27, 28] .
b) The noise due to random gamma ray pairs is reduced by narrowing the coincidence window, lowering the count rate, and using long narrow collimators. The "time-of-flight" machines have an effective timing window of about 400 picosec, for each region of the image, although the total timing window must be set up for at least 6 nsec for a body imaging system using a ring source near the detectors for calibration and attenuation correction. Brain imaging systems using a ring source for attenuation correction are limited to a 4 nsec resolving time.
c) The number of true counts in the final image is of prime importance in determining image quality. In a filtered back-projection image for uniform distribution, if the spatial resolution is improved by a factor of 2, the number of counts required for the same noise per resolution element is increased d)
e)
by a factor of 8. The factor is less than 8 for "timeof-flight" systems since the position of each event is known with moderate accuracy. The factor would be 4 if the "time-of-flight" information were accurate enough to position each event in the correct resolution element, since no image reconstruction would be required [29] . The number of counts in the image can be increased by counting longer, increasing the count-rate, or bringing the detectors nearer the patient.
The reconstruction filter can be tailored to match the required image resolution. If a device were built with 5 mm resolution limited by the detector size, and only 10 mm resolution is required in the final image, then by reversing the argument of the previous section only 1/8 of the counts would be required. This is known as the "signal amplification technique" (SAT) [30] .
The attenuation of gamma rays by body tissue must be compensated for in the final image. Since most gamma rays are scattered rather than completely absorbed, attenuation correction and scatter compensation are closely linked. Imaging a ring source with the patient in place to correct for attenuation also compensates for scatter in the final image as if the source distribution in the final image is uniform. This compensation is incomplete in the case of an asymmetric final distribution of activity in the emission image to be compensated. A transmission scan does not compensate for scattered events outside the plane of the scan. Often one parameter can be optimized only by trading off performance in another area. As the effects of each parameter on the final image are better understood, compromises can be made when designing a new device to tailor it to its intended use.
Radiochemistry
The positron emitting radionuclides most commonly used in conjunction with PET are listed in Tab. I, along with some of their physical characteristics. It will be noted that three of them (oxygen, nitrogen, and carbon) are constituents of every living organism, making them especially reliable for labelling naturally occurring substances. Unfortunately, these three radionuclides have short half-lives, and the chemical manipulations possible with them are limited. Furthermore, their use is limited to centres with an on-site cyclotron. Fluorine-18 can also be used in centres within two hours of the cyclotron. A small medical cyclotron with external energies of about 6. Fluorine-18 is an important radionuclide for the synthesis of positron-labelled radiopharmaceuticals because its half-life is just long enough to allow quite complex radiochemical manipulation. Its Van der Wals radius is very close to that of hydrogen (rF 1.35A °; rH --1.1A o) [33] . Consequently the biochemical properties of 18F-labelled analogues e.g. 18F-labelled 2-deoxy-2-fluoro-D-glucose (18F-2-FDG or FDG) and 2-deoxy-D-glucose [31, 32] are not greatly different from natural substrates.
Radionuclide production
In a "no-carrier added" synthesis the absolute amount of material is very small (Tab. I). These small yields constitute an additional drawback in the synthesis of biologically active molecules since the yield of chemical reactions is mass dependent and special techniques are needed to manipulate small amounts. Unfortunately, most positron emitting raPositron emission tomography 237 dionuclides (with the exception of 6SGa, which is available in the form of a generator), can be used most effectively only when produced in an on-site cyclotron.
Since the production of 77Kr and 75Br needs even higher energy cyclotrons [60, 61] , this review will be limited to 150, 13N, lie and lSF, which can be produced in good quantities with small medical cyclotrons. We shall also limit our discussion to the radiopharmaceuticals labelled with oxygen, nitrogen, carbon, and fluorine. These four radionuclides can usually be produced using a naturally occurring or an enriched isotopic mixture (Tab. II) as a target material. A naturally occurring isotopic mixture is obviously preferable.
Tab. III lists some simple molecules labelled with the four positron emitting radio-isotopes, which in most cases are used as intermediaries. Since 150 has a halflife of only 2 min it has been used to produce labelled gases in an on-line mode [41] [42] [43] [44] [45] . Nevertheless, water can be labelled with 150 in a batch mode, and 150 can be used for blood flow measurements [45] . Production of these intermediaries has been the subject of several reviews [51] [52] [53] . In many cases cyclo- 180 (p, n) lSF 9 * n.m. stands for natural mixture ** It is approximate particle energy in MeV on the target material needed to produce enough of radioisotope to synthesize radiopharmaceutical for PET-studies.
tron manufacturers offer systems that are capable of choosing automatically various nc and 150 labelled gases (CO, CO2 and 150-O2). Many of these gases, e.g. nc-labelled nitrosoureas [38, 39] using 11@ phosgene [40] could be prepared in an on-line mode, allowing us to do an on-line synthesis. A radionuclide requiring special attention during production and use is fluorine-18. To date, molecular fluorine has been the most commonly used form of lSF, as it is required for the synthesis of lSF-2-FDG. Production and extraction of molecular fluorine [46] [47] [48] and hydrogen fluorite [34] from the target box have received special attention. High [46, 47] and low [48] pressure targets have been described for the production of lSF-F2, as has a system that converts 18F-HF into aSF-F2 [34] . Recent reports indicate that the most commonly used radiopharmaceutical, laF-2-FDG, could be synthesized by using lSF-fluoride [49, 50] , but a synthesis yielding levels of ISF-2-FDG needed for a PET study has not yet been reported. "No carrier added" 18F-fluoride could become an extremely important intermediary for the synthesis of lSF-labelled radiopharmaceuticals, e.g. for spiroperidol [54, 55] , because the specific activity of lSF-compounds is much closer to the carrier-free level than the specific activity of nC-compounds [54] [55] [56] . Small volume targets capable of producing hundreds of mCi of "no carrier added" lSF via an 180(p, n) reaction have been reported. Since the amount of radioactivity is very high there is no real need to recover 1SO-enriched water [37] , although this is possible [361.
Since the half-life of carbon-11, a natural constituent of all organic molecules, is 20 min, 40-60 minutes are available for radiochemical synthesis. The half-life is short enough to permit a second test in a single day on the same subject. The use of an individual as his own control may assume great importance because of the large spread of the physiological parameters between individuals and the difficulty of defining normal physiological levels [35, 37] .
A remotely operated system for the production of 11C-CH3I, an important intermediary in the synthesis of nC-labelled compounds [65] , has been developed.
Radiopharmaceuticals
Synthesizing a labelled compound and using it in a human PET study are two different matters. Several syntheses (e.g. the triazine reaction [73, 74] ) have yielded a labelled compound, but the level of radioactivity at the end of the synthesis was not sufficient for a PET study.
Special considerations must be taken into account when labelling with shortlived positron emitters. These include: a) optimal position of the label needed; b) synthetic routes needed and their ability to place the label at the optimal position; c) availability and stability of the starting material and labelled intermediary; d) time needed to complete synthesis, purification, and sterilization of the final product.
A labelled compound can be a natural substrate (e.g. labelled amino-acids), an analogue of a natural substrate (e.g. 2-FDG), or an agonist or antagonist of a natural substrate (e.g. spiroperidol) (see Tab A detailed review of 13N, 11C, and lSF radiopharmaceuticals recently published by the National Academy of Sciences [66] , notes that the most commonly used radiopharmaceutical for PET studies is laF-2-FDG, which was originally [67] synthesized by reacting ~8F-F2 with thriacethylglucale. Its popularity prompted the development of several remotely operated systems [67] [68] [69] [70] . A more efficient synthesis of lSF-2FDG was recently designed [71, 72] using lSFlabelled acetylhypofiuorite as an intermediary. The importance of the label's place can be demonstrated by comparing 18F-2-FDG and lSF-3-deoxy-3-fluoro-D-glucose. The second compound is not a substrate for hexokinase, and cannot be used as a tracer in the measurement of glucose utilization. 18F-3-deoxy-3-fluoro-D-glucose was suggested as a tracer for the measurement of glucose transport [87] , but its use as a transport label is probably not paramount since the synthesis of 11C-3-0-methylglucose (a transport tracer [35] ) is much easier.
As PET technology became more sophisticated, the search for positron labelled receptor antagonists and agonists intensified. Although an 11C-labelled synthesis of spiroperidol has been reported [56] , it has not yet been used for PET studies. Spiroperidol was also labelled with "no carrier added" 18F-F, yielding a compound of sufficient specific activity (10 000 Ci/mmol) [54, 55] to allow in vivo quantitative measurement of the distribution of dopaminergic receptor sites in humans. 11C-phosgene is an important 11C-intermediary, having been used in the synthesis of a pH indicator DMO [75, 76] and of nitrosourea [38, 39] , both of which have been used for PET studies. l~C-labelled carbon dioxide is an intermediary that can be used as such in the synthesis of tiC-glucose by biosynthesis in algae [77] and spinach [78] . It has also been used to label HC-carboxylic acid by the carbonation of a Grignard reagent [80] . The Grignard reaction is a convenient synthetic route for sic-labelled carboxylic acids since it is a fast, "one-step" chemical reaction that provides a good chemical yield. Palmitic acid as an energy substrate in myocardium has been of great interest in PET myocardial studies. 18F-labelled analogues of fatty acids have also been prepared [79] .
11C-labelled hydrogen cyanate has been used in the synthesis of hydantoins [80] and 11C-2-DG [81] . 11C-methyl iodide has been used in the synthesis of iodoantipyrine [83] and several drugs [82] . It may be considered as a general reagent for introduction of the llC-methyl group because it is highly reactive, and reacts quite easily with amino groups yielding substituted amines. It will also react under a basic condition with many carbonyl and -OH groups yielding 11C-labelled compounds [84, 85] . Several aminoacids have recently been labelled with ~1C in the carboxyl group [58, 64] as well as in other positions (3-laC-phenylalanine [63] , and ~lC-methyl methionine [62] and L-(4-11C) aspartic acid [57] ).
13N-, with its ten-minute half-life, has not been widely used in the synthesis of radiopharmaceuticals for PET studies. The reason for the limited use of 13N is definitely its short half-life. It may be used more frequently once fast PET scanners are developed.
During the next few years radiochemical developments will greatly influence the application of PET technology in in vivo biochemical studies in humans.
Novel synthetic methods for labelling agonists and antagonists to study opiate, dopaminergic, muscarinic, and other receptors are being developed in many PET centres. 18F might again prove to be a very important radionuclide, because many of these agonists and antagonists contain fluorine in their molecules. Completely automated syntheses are not expected to prove really useful, because radiochemical technology is advancing so rapidly that expensive, cumbersome systems are rapidly outdated. However, remotely operated syntheses will be increasingly used to reduce radiation exposure to radiochemists.
It is unlikely that nitrogen-13 will be used much in the future because its ten minute half-life limits the time for the synthesis and purification needed to obtain an amount adequate for PET-studies.
alC and 18F intermediaries are being used with increasing effectiveness to label biologically active molecules.
Tracer techniques
PET allows the quantitative and noninvasive measurement of local tissue concentrations of radioactive tracers administered to the human body in a manner similar to that of tissue autoradiography. Suitable labelled compounds together with the appropriate tracer kinetic model allow study of a variety of functional processes in vivo [32, 88, 89] .
Measurement of blood flow
The tracer methods for quantitative measurement of blood flow with PET are based on the principle of non-metabolized diffusible tracers developed by Kety and Schmidt [90] . Four different approaches have been exploited to study blood flow by means of PET.
Continuous inhalation technique
This approach, originally developed by Jones et al. [91] [92] [93] [94] , uses the continuous delivery from a nearby cyclotron of the short-lived tracer gas C1502 which, under the action of carbonic anhydrase, is converted into H2150 in the capillaries at the pulmonary alveolar level. After the subject has breathed C1502 for 10 minutes, a dynamic equilibrium is established: the tissue radioactivity due to H2150 entering a tissue element of volume V at a steady arterial concentration Ca is balanced by the continuous removal of H2150 through the blood and by radioactive decay of 150 (decay constant )~ = 0.338 min-1). The steady state tissue concentration, Cb, of H2150 is related to blood flow (ml per min per 100 cm 3 tissue) in the following manner:
Knowledge is required of the tissue-blood partition coefficient p for water [95] (pgrey = 1.04, pwhite = 0.88, p .... = 0.95) and of the arterial equilibrium concentration of 150, Ca. Also, the counting efficiency ratio between the tomograph and the well counter, which serves for the blood sample counting, has to be established by appropriate phantom studies (cross-calibration) [96] . This elegant model has been analysed by several authors [9%99] and some of its limitations are mentioned here. As seen from equation (1), the relationship between Ca, Cb and blood flow is not linear [92, 100] and the error in calculated CBF increases with increasing blood flow due to the uncertainty in the measured parameters, particularly if the value of Ca/Cb approaches the value of 1/p. The method is therefore highly dependent on errors in the measurement of Ca and Cb [99, 101] . An accurate determination of Ca requires a steady supply of C1502 from the cyclotron as well as a relaxed steady state of the subject. Changes in respiratory pattern caused for example by physical and mental stress can produce large fluctuations in Ca [102] . Averaging of multiple arterial samples tends to reduce the error in CBF [103] . The non-linearity of the equilibrium CBF model also leads to a systematic underestimation of CBF if, as is the case for most of today's tomographs, the analysed region of interest is inhomogeneous and contains a mixture of grey and white matter [101] . Finally, since approximately 5 to 10 minutes of scanning time are required to image a series of simultaneous brain slices, a complete study might last up to one hour, during which steady imaging conditions have to be maintained. This steady state model, however, has the advantage of good image quality and high spatial resolution.
Dynamic integral technique
In an attempt to overcome the shortcomings of the original equilibrium CBF model the St. Louis group [104, 106] developed a technique for the quantitative determination of CBF by means of a method similar to the tissue autoradiographic technique originally proposed by Landau and colleagues [105] . The Raichle technique is based on Kety and Schmidt's [107] global compartmental model which describes the transport of a flow limited tracer in blood and tissue. This model, extended here to the regional level, is based on the following equation: (2) C(t) = f. e -kt* Ca(t) where * denotes the convolution operation and C(t) is the tissue tracer concentration, f the blood flow through volume element V, k=f/p with p being the equilibrium tissue-blood partition coefficient of the tracer used and Ca(t) the arterial tracer concentration. In practice, PET data is accumulated over a finite period of time. This means that equation (2) has to be integrated over the time of the PET scan: t2 ta (3) f C(t) dt = f" f (e-kt* Ca(t))dt tl h
The diffusible tracer commonly used with this method is H2150, which is injected intravenously as a bolus (-70 mCi). Data collection is completed within 40 seconds during which frequent arterial samples are drawn from the radial artery. The short duration of the study is an obvious advantage of the method. Furthermore, unlike the equilibrium approach discussed previously, this technique yields the exact average blood flow for a brain tissue mixture of grey and white matter as has been shown by simulation studies [108] . One source of error of the present method, however, is the timing of the arterial input function, Ca(t), with respect to the PET head data. A delay of two seconds already gives errors of 10% in CBF. Exact timing is achieved by accurately measuring the appearance time of the bolus in the head and in the radial artery [109] . Phantom studies are again necessary to relate the arterial data to the PET head data units.
A method based on the same approach has been proposed by Ginsberg et al. [110] , who use special tracer infusion schedules so that Ca(t) can be approximated by a low order polynomial. Equation (3) can then be easily solved for CBF by means of a look-up table method. This consists of evaluating the right side of equation (3) for a given set of blood flow values and comparing them to the experimentally measured tissue tracer concentrations (left side of equation (3)) for each pixel of a cross sectional brain slice. Both techniques have been successfully validated in animals or on humans. It should be remembered that this dynamic approach is possible because of the rapid scanning capacity of the tomograph [104] .
Clearance technique
Attempts have been made to adapt to PET the classical clearance approach, originally developed for the use with gamma emitting inert tracers. [116] . This tracer appears to have the desirable feature of a nearly uniform tissue-blood partition coefficient for the entire brain, i.e. Pgrey ~ Pwhite. More recently, Huang et al. [117, 118] have developed a dynamic CBF method based on the central volume principal (i.e. F/V = 1/x where ~ is the mean transit time of tracer through the volume of distribution V and F is blood flow in ml/min). These authors reformulate the flow equations in terms of integral values of tissue and arterial tracer concentrations and adapt them to a time-dependent PET reconstruction process. They use the bolus inhalation of ClSO2 or intravenous injection of H2150. Data are collected over 8-10 minutes. Instead of reconstructing PET images of tissue concentration at short time intervals, pictures of V and r are reconstructed from appropriately selected projection data taking advantage of the fact that integration in time and PET reconstruction in space are linear operations whose order can be interchanged [119] . This dynamic technique is also invasive in the sense that arterial blood sampling is required. But the technique should be applicable to other diffusible tracers where arterial sampling might be replaced by expired air monitoring.
ium ion (13NH4 +) [122, 123] . This portion is a function of blood pH [125] . Furthermore, the trapping of ammonia involves its rapid incorporation into the large glutamate pool of the body [124] . The pool size may change considerably in pathological states and thereby influence the extraction of 13N-ammonia by the brain. It is therefore difficult or impossible to get quantitative CBF information by the 13N-ammonia technique, particularly in pathological conditions with altered blood-brain barrier characteristics. The method, however, provides an index of cerebral perfusion.
Cerebral blood volume
Due to its simplicity and accuracy, the measurement of regional cerebral blood volume, CBV, was one of the first measurements carried out with PET. Besides its importance as a potential index of regional CBF [126] , regional CBV is useful in combination with other PET measurements. For example, accurate assessment of regional CBV is important for the exact calculation of the regional cerebral oxygen consumption rate [97] . It is also required for the determination of tissue haematocrit or the distinction between the vascular and extravascular concentrations of a given radiopharmaceutical [88] . Its measurement is based on a straightforward equilibrium model [127] . 
Metabolic trapping technique
This stationary CBF method was developed on the microsphere model [120, 121] . 13N-labelled ammonia, injected intravenously, is rapidly extracted from the plasma by cerebral tissue where it is metabolically trapped and retained for a long time [122] [123] [124] . Ammonia was believed to behave like microspheres, i.e. its stationary distribution in tissue would reflect regional CBF, an ideal condition for quantitation by PET. This method has a number of serious disadvantages, however. First, ammonia is not freely diffusible and therefore not strictly flow limited, since some portion of the tracer in the blood always exists in the nondiffusible form of an ammonThe factor 0.85 is the ratio of haematocrit for cerebral tissue and large peripheral vessels. The quantities 9 and d are the densities of cerebral tissue and blood respectively.
Measurement of metabolism 4.3.1 Glucose metabolism
The quantitative capabilities of PET have made possible the measurement of regional substrate utilization in vivo. This is illustrated here by the measurement of cerebral glucose utilization in man using either the glucose analogue lSF-2-FDG [31, [128] [129] [130] or laC-labelled glucose [131, 132] . The use of rather sophisticated mathematical models and experimental set-ups allows us to calculate metabolic rates from quantitative PET images and blood data.
Deoxyglueose method: In general, the rate of a chemical reaction measured by tracers can be calculated as the ratio of labelled product formed in the time interval from administration of the substrate until a given time T, and the integrated specific activity of the precursor in tissue multiplied by an isotope effect correction factor (lumped constant) which applies if tracer and tracee are not the same [133] . Using this principle, Sokoloff et al. [134] have derived an operational equation for the measurement of the cerebral glucose metabolic rate using the analogue 18F-2-deoxy-D-glucose (FDG) [31, 128] . Deoxyglucose (DG) is a competitive substrate with glucose and is transported bidirectionally across the blood-brain barrier by the same carrier that transports glucose. In brain tissue, it is phosphorylated like glucose by hexokinase to produce 2-deoxyglucose-6-phosphate (DG-6-P). Unlike glucose-6-phosphate, however, which eventually is metabolized further to COz and water, DG-6-P is trapped in cerebral tissue for at least 45 minutes since it is a poor substrate for further metabolism. This fact, plus the rapid decline of plasma DG-concentration to a low constant level, and the relatively rapid precursor pool turn-over rate represent ideal model conditions for measurement with PET. The cerebral metabolic rate of glucose (CMRG1) in b~mols of glucose per minute per 100 g tissue can then be calculated as follows: [31, 128] :
stant which is composed of ratios of MichaelisMenten kinetic constants and distribution volumes for glucose and deoxyglucose. Although LC can be assumed to be reasonably stable in physiological conditions, it may change in pathological states such as severe hypoglycaemia [135, 136] .
The Sokoloff model was extended by Phelps et al. [129, 130, 137] who included the dephosphorylation step (rate constant k*4) of FDG-6-P in their operational equation. These authors also developed a method to circumvent arterial blood sampling by using arterialized venous blood from the hand immersed in a glove box type water bath heated to 42 °C. An alternative formula for the calculation of the glucose metabolic rate, also including k*4, was proposed by Brooks [138] . Although only about one tenth of k*3 in magnitude, the effect of k*4 may become significant if PET imaging is done at later times (e.g. after one hour). Average lumped and rate constants as established by Huang et al. [130] are routinely used with this model. The derivation and validation of this extended model, together with results on its error sensitivity to changes in rate and lumped constantsaregiven elsewhere [129, 130, 135, 137, 139] .
Glucose method: Carbon-ll labelled glucose can also be used to measure CMRGI, as Raichle et al. [131, 132] 
LC[0fTcp(t) dt -e -(k~ + k~)T 0fTcp(t)e (k~ + kj)t dt]
Here, k*l and k*z are the forward and reverse plasma-tissue rate constants and k*3 is the phosphorylation constant for FDG. C*i(T) is the tissue tracer concentration at time T (phosphorylated and nonphosphorylated FDG), Cp and Cp* are the plasma concentration of glucose and FDG respectively, and LC is the lumped constant. In addition to the PET image (C*i(T)) taken at approximately 45 min. after tracer administration when the blood specific activity is low, the blood data, the lumped constant, and the various transport rate constants must also be known. It has been shown that the terms involving the rate constants become small as the time after injection increases [128] [129] [130] 134] . Average rate constants, determined on a series of control subjects, may therefore be used. In pathological conditions such as extreme states of hypometabolism, however, this procedure can lead to inaccurate estimates of CMRG1 [135] . Similar reservations apply to the lumped conconstant being equal to one since tracer and tracee are identical. Unlike DG, however, HC-glucose is rapidly broken down and the labelled products diffuse out of the tissue. Since egress of tracer from the brain, however, is low during the first five minutes after administration, PET-imaging must be carried out within the first few minutes. This time restriction requires that a correction be applied for free tracer in blood and tissue. Regional CBV must therefore be known. Since the imaging has to be done early, the glucose method also becomes more susceptible to the use of average rate constants. The advent of rapid efficient multi-slice tomographs, however, makes possible the on-line determination of those parameters in each subject as well as of the local metabolic rate of glucose. Although theoretically sound, this method appears to be susceptible to errors introduced by the various corrections necessary and is therefore difficult to implement in practice.
Cerebral oxygen metabolism
The methods outlined for the measurement of brain glucose metabolism are not directly applicable to the measurement of brain oxygen utilization. Although 1so-labelled molecular oxygen is readily available for inhalation by the subject, 150-oxyhaemoglobin is rapidly converted to 150-labelled metabolic water. This process results from aerobic metabolism involving molecular 150 extracted from the arterial blood to the cerebral tissue. After its rapid egress from the tissue, this 150-labelled water starts recirculating in the blood stream. Upon continuous inhalation of 1502, the brain tissue H2150 concentration, Qo, derives from two sources, namely oxygen-15 labelled metabolic and recirculating water extracted into cerebral tissue. The tissue 150-activity, therefore, can be expressed as [91] [92] [93] [94] :
where Co is the arterial equilibrium 1502-concentration, OEF the cerebral oxygen extraction fraction (OEF = (Ca-Cv)/Ca with Ca and Cv representing the arterial and cerebral venous oxygen contents respectively), Gw the arterial concentration of recirculating water, F the blood flow through a tissue region with water distribution volume V and ~. the radioactive decay constant for 150. Combining 02 inhalation data with data obtained during the continuous inhalation of C1502 for the measurement of CBF, the local oxygen extraction fraction, OEF, can be expressed as follows:
Here, Qw and Cw are 1SO-concentrations in brain tissue and arterial blood, respectively, obtained during continuous C1502 inhalation. Crw and Co have to be derived from the 150-activity in whole blood (Cb) and plasma (Cp) during 1502-inhalation:
where A is the ratio of 150 concentration in whole blood to that in plasma during C1502 inhalation and
From these measurements, the regional OEF can be determined. Initially [91, 93] , the ratio of the 1502 and the C1502 inhalation equilibrium brain images was used as an index for OEF. It can be shown that the cross-calibration factor which accounts for the different counting efficiencies of the tomograph and the blood sample counter (well counter) cancels from the calculation of OEF. The regional cerebral metabolic rate of 02 (rCMRO2) in ~tmols of 02 per minute per 100 g of tissue is then given by:
where [02] is the total blood oxygen content (= 20 ml of 02 per 100 ml of blood). Lammertsma et al. [97] have shown that, in order to calculate rCMRO2, a blood volume (CBV) correction has to be introduced in the calculation of OEF. This can be achieved by measuring CBV with C150 or 11CO.
Without this correction, OEF may be overestimated by up to 30% due to the 150-activity in the blood. A complete oxygen metabolic PET study therefore typically consists of a sequence of three measurements characterized by the successive inhalation of 1502, C1502, and caSo or 11CO [94, 140, 141] .
Raichle et al. [142] recently proposed a dynamic, single-breath 1502 inhalation approach for the measurement of rCMRO2 by means of a rapid and efficient multislice tomograph. This technique, with a data collection time of only 40 seconds, has already given satisfactory results in humans.
Protein synthesis
The same basic principles applied to the measurement of cerebral glucose metabolism may also be used to measure local cerebral protein synthesis [143] . Using L-leucine labelled with carbon-ll in the carboxyl position, Phelps et al. [32] have estimated the global rate of incorporation of L-leucine in proteins for humans. The modelling conditions appear to be similar to the deoxyglucose situation, i.e. the labelled leucine in plasma rapidly decreases to a constant low concentration, membrane transport and turnover rate of the precursor pool are rapid, and the end product resides in a large protein pool with a slow turnover rate. Similarly, Comar et al. [62] and Bustany et al. [144] have synthesized and used 11C-L-methionine for the measurement of protein synthesis. By means of a simple initial model consisting of three compartments they managed to estimate the global rate of incorporation of L-methionine into proteins for humans. Despite several simplifying assumptions in both models, the L-leucine and L-methionine data appear to be consistent. This fact demonstrates the potential usefulness of PET for the quantitative assessment of protein synthesis and metabolism.
Dosimetry
The radiation dosimetry for some of the current PET methods is summarized in Tab. V. The calculations were carried out according to the absorbed fraction Tab. V. Estimated radiation doses for some of the current PET techniques (see also [1] [2] [3] [4] * Assumes the gas is administered for one hour at a rate of i mCi/min. mation on the regional alteration of the cerebral metabolic rate and the functional state under physiological and pathological conditions. Changes of r C B F generally parallel the regional cerebral metabolic rate under most physiological and some pathological states [32, 145] . However, it is well-known that in many pathological states r C B F changes are uncoupled from the regional cerebral metabolic rate [146] [147] [148] [149] .
Normal subjects
U n d e r normal conditions with eyes and ears open, rCMRG1 and r C M R O 2 values are symmetrical between the left and right cerebral hemispheres [150, 151] (Fig. 1) . However, w h e n eyes and ears are
Clinical application
Over the past 30 years, knowledge of physiological and biochemical processes in various organs of the body has b e e n gained mainly by in vitro procedures. To date, research has been h a m p e r e d by the difficulty of making direct, quantitative m e a s u r e m e n t s of regional dynamic and biochemical events. PET, which can provide quantitative and three-dimensional mapping of the distribution of radionuclides in any organ of the h u m a n body, is analogous to the quantitative autoradiographic m e t h o d used in experimental procedures, but it has the added advantage of allowing in vivo studies. Since glucose and oxygen are almost exclusively the substrates for cerebral metabolism, P E T m e a s u r e m e n t of the regional cerebral metabolic rate of glucose (rCMRG1) using 18FDG, and of oxygen (rCMRO2) using 150 provides infor- closed, there is a significant reduction of rCMRG1 in the right cerebral hemisphere, particularly in the right inferior prefrontal, right posterior superior temporal, and associated visual cortex [152] .
Regarding auditory stimulation, the Philadelphia group [153, 154] reported that when a factual story was recounted in a monophonic tone, the stimulation produced a 20 to 25% increase in rCMRG1 in the entire right temporal lobe regardless of the side of the ear stimulated. More recently, the UCLA group [155] reported that verbal stimuli produced increased rCMRG1 in bilateral posterior temporal and left fronto-temporo-occipital areas. On the other hand, nonverbal stimuli produced a diffuse right-sided hypermetabolism of rCMRG1, except in persons who had some musical background and used highly analytic strategies as demonstrated by left posterior temporal hypermetabolism.
In studies of aging, the UCLA group [156] reported a steady and diffuse mild decrease of glucose metabolic rate with advancing age. (At age 78, mean rCMRG1 was 26% less than that at age 18.) rCMRG1 declined with age at a rate faster than that reported by the Hammersmith group [94, 101] for rCMRO2. This decline was possibly due to increasing altered pathways for glucose utilization or to increased oxidation of ketone bodies or other alternative substrates [157] .
The NIH group recentlyreported that mean hemispherical and mean grey matter rCMRG1 values were not significantly altered with advancing age in healthy men [202(A & B)]. However, the NIH study was performed under a complete sensory deprivation state (caused by covering the eyes and blocking the external auditory canals). Sensory deprivation is known to reduce rCMRG1 values significantly (over 35%) in normal subjects [152, 203] . rCMRG1 values for aging as reported by the NIH were about 40% less than those reported by the UCLA group, which performed its rCMRG1 studies after simply covering the subject's eyes. The UCLA results indicate significant reduction with advancing age [156, 203] .
As for motor activation, at the MNI we noted that complicated finger movements produced a significant increase of rCBF in both the supplementary motor, the contralateral motor hand, and the contralateral globus pallidus areas [158] .
Cerebrovascular diseases
Among the most critical pathophysiological changes occurring in cerebral ischaemia are those to be found in rCBF, rCMRO2, rCMRG1, cellular acidosis, and biochemical disturbances initiated by abnormal intracellular ion homeostasis, all of which can be measured quantitatively with existing PET techniques. Several centres have used PET to investigate pathophysiology in cerebral ischaemia and to evaluate prognosis and therapy in stroke [187] [188] [189] .
Two types of focal disruption of the normal coupling between rCBF and metabolism have been observed to follow cerebral ischaemia. In the early stage of cerebral ischaemia, a significant reduction of rCBF associated with increased rOEF has often been noted, a phenomenon that has been termed "misery perfusion" [159] . The other common focal disruption in the blood flow-metabolism coupling is a luxury perfusion in which rCBF exceeds metabolic demands for oxygen, as demonstrated by rOEF [146, 160] . This phenomenon usually occurs in ischaemic areas less than four weeks old and in most cases was found under normal or reduced rCBF.
Reduced rCMRO2, which has been detected as early as 24 hours after the stroke was found to be a more reliable prediction of cerebral ischaemia [92, 147, 161] . The Hammersmith group [162] reported that when rCMRO2 fell below 58 ~mol/100 ml/min in the ischaemic lesion the final clinical outcome was always poor. Conversely, higher rCMRO2 values were associated with a good prognosis. The three following therapeutic and prognostic possibilities, based on rCMRO2 levels, exist in patients with stroke [146] . a) In the first stage, reduction of rCBF associated with relatively normal rCMRO2 represents an ischaemic lesion with viable tissue that would benefit from medical and surgical treatment to increase cerebral perfusion, such as endarterectomy or an extracranial and intracranial bypass procedure.
b) In the second stage, reduction of rCBF associated with intermediate reduction of rCMRO2 represents an ischaemic lesion with viable tissue but metabolically disturbed brain tissue, which may benefit from treatment to improve cerebral metabolic demands.
c) In the third stage, marked reduction of rCBF associated with profound reduction of rCMRO2 and rCMRG1 below the critical value for viability indicates candidates for more conservative treatment (Fig. 2 ).
Epileptic disorders
Epilepsy is a complex sequence of functional brain disturbance in which there is often no apparent structural abnormality [163, 164] . When neurosurgical treatment of partial epilepsy is anticipated, delineation of the epileptogenic focus in a localized area of the brain becomes crucial [165, 166] . At the present time localization of an epileptogenic focus relies primarily on electrophysiological techniques. Recent studies indicate that PET data for rCMRG1, rCMRO2, and rCBF can provide information complementary to electrophysiological studies. PET findings on the interictal or ictal phases of partial epilepsy may help to determine whether the location of an electrical abnormality derives from the primary lesion or is propagated from another site [167] . Recent PET findings indicate that in partial epilepsy the location of hypometabolism of rCMRG1 during the interictal phase is closely associated with the epileptogenic focus delineated by interictal and ictal electrophysiological recordings [151, [168] [169] [170] . In most partial epilepsy cases there is a similar tendency during the interictal phase [170] towards reduced rCBF and rCMRO2 in the zone of hypometabolism of rCMRG1.
Brain tumours
Recent PET findings indicate that the degree of hypermetabolism of rCMRG1 correlates with the malignancy of brain tumours [149, [171] [172] [173] . However, rOEF is found to be markedly reduced within malignant tumours and in adjacent brain tissue in spite of increased or normal rCBF in the same areas. This phenomenon indicates a marked increase of the nonoxidative glucose utilization rate, probably involving nucleic acid synthesis in the malignant turnout [149] (Fig. 3a and b) . Our recent studies on the pharmacokinetics of 11C-labelled 1,3-bis(2-chloroethyl)-nitrosourea (BCNU), widely used for chemotherapy of brain tumours, indicate that the initial concentration of BCNU is proportional to rCBF. However, retention of the BCNU in the tumour exceeds that in normal brain tissue [149, 174] (Fig. 4) . These initial findings suggest that PET can help define the biological nature of brain turnouts in terms of type, blood supply, and metabolic characteristics, and assist in the selection of proper therapeutic intervention.
In conjunction with a nondiffusible tracer such as 6SGa-EDTA, PET can also detect at an early stage malignant brain tumours involving minimal structural and vascular changes, but significant alteration to the blood-brain barrier well before they can be spotted on a CT scan [111, 175] .
Other brain disorders
PET techniques have also been used to investigate dementia [176] [177] [178] , Huntington's disease [179] , and psychiatric disorders [86, [180] [181] [182] . Conventional clinical investigations have failed to provide specific insights into the natural history of these disorders. Fig. 3 . Biochemical images of a malignant brain tumour which show markedly increased rCMRG1 (a) and a local increase of rCBF associated with a marked reduction of rOEF (b) in the recurrent area of the tumour (arrow).
Cardiac disorders
The commonest cardiac disorder in adults is ischaemic heart disease caused by inadequate blood flow to the cardiac muscle. 11C-labelled 11CO, which has a high affinity to bind with the haemoglobin in the cells to form 11C-carboxyhaemoglobin, has been used to estimate changes in the cardiac blood pool [190] . 13NH3 was found to be useful for measuring myocardial perfusion [191, 192] , and lSFDG proved excellent for measuring myocardial glucose metabolism [193] . If blood flow and oxygen delivery into the myocardium are reduced, the activity of beta oxidation and the citric acid cycle decreases or ceases entirely. A shift from free fatty acids (FFAs) to glucose metabolism occurs in response, and the myocardium attempts to produce high-energy phosphates through either residual oxidative capacity or anaerobic glycolysis. Although the myocardium continues to extract FFAs, their entrance into the beta oxidation spiral is impaired. HC-labelled palmitic acid has accordingly been used to evaluate myocardial FFA metabolism in humans [183, 194, 195] . Determination of glucose and F F A by lSFDG and 11C-palmitic acid with PET provides a means to investigate changing aerobic and anaerobic metabolic rates in ischaemic heart disease in man. The motion of the heart during an imaging procedure reduces the resolution and contrast in the images and seriously compromises the method's capability in extracting quantitative information from the cardiac images. To overcome these problems [196, 197] an electrocardiographic, synchronized, multiple-gated data acquisition and deconvolution technique for correction of spillover fractions was recently applied. Time-of-flight positron emission tomography will further improve cardiac imaging and quantification of image data [198] [199] [200] [201] . Fig. 4 . Pharmacokinetics of 11C-BCNU (antitumour agent) in the brain tumour shown in Fig. 3 . The initial concentration of HC-BCNU is the same as that in normal cortex, but there is a significantly greater retention of BCNU and its breakdown products in the tumour site (arrow) than in the normal cerebral cortex a few minutes after the intravenous injection.
Neurotransmitters
Over the past two decades, several neurotransmitters have come to be recognized as the specific messengers for interneuronal communication apparently associated with abnormal neurological and psychiatric states. PET studies of the distribution of several neurotransmitters have recently been done in humans using lSF-labelled 6-fluoro-L-dopa [204] and 11C-labelled 3-N-methylspiperone [205] . As PET imaging devices become more sophisticated and further advances are made in radiochemistry, PET imaging of neurotransmitters should improve our understanding and management of many puzzling neurological and psychiatric disorders.
Pharmacological research
While PET techniques have been extensively applied for the investigation of blood flow and various metabolic rates in the human body, PET technology has great potential for the in vivo study of the pharmacokinetics of many drugs, especially carbon-ll labelled compounds that behave chemically or biochemically in the same manner as the natural compound. We have applied these methods to investigate the anti-turnout agent 11C-BCNU [149, 174] . Recently, Comar and associates reported on the use of labelled ligands for the study of neuroreceptors, e.g. carbon-ll labelled etorphin for the opiate receptors [184] , pimozide for dopamine receptors [59] , and flunitrazepam for the benzodiazepin receptors [185] . Preliminary results in baboons have shown promising results [186] .
Conclusion
This review of recent advances in the investigation of biochemical and physiological processes using positron emission tomography provides, we hope, a perspective on future applications of this method.
